Kali Research LLCResearch Access Portal

All compounds are designated Research Use Only (RUO). Not for human consumption, veterinary use, or clinical application.

Research Compound CatalogMetabolic ResearchRetatrutide Research Profile
Metabolic Research
Research Use Only

Synthetic Triple Incretin Receptor Agonist Peptide

Retatrutide

Triple Incretin Receptor Agonist Peptide

Research StatusLiterature Reviewed Through: July 2026
Research Use Only
Updated Periodically

Research Profiles are reviewed periodically as new peer-reviewed literature becomes available.

Available Strength
10 mg / vial
CAS Number
2381089-83-2
Metabolic Research laboratory research
Metabolic Research
Research at a Glance

Major published findings — summarized in under 30 seconds.

1
Significant reductions in body weight have been observed in multiple clinical studies, with some participants losing a substantial percentage of total body weight.
2
Improvements in blood sugar regulation have been reported across study populations.
3
Research suggests broader metabolic effects than earlier single- or dual-pathway compounds in the same class.
4
Large Phase 3 clinical studies are currently ongoing.
5
Long-term safety and durability of effects continue to be evaluated in active research programs.

What Is This Compound?

Retatrutide is a research peptide being studied for its effects on body weight and metabolic health. Unlike earlier compounds in this class, it activates three separate biological pathways at once — pathways that influence how the body regulates blood sugar, stores fat, and uses energy. Because of this broader activity, researchers have been studying whether it produces stronger or more durable metabolic effects than compounds that target only one or two of these pathways. It has been evaluated in large human clinical trials, making it one of the most thoroughly studied compounds in this category. Research is ongoing, and long-term data continue to be collected.

Continue below to see what published research has observed so far.

What Has Research Found?

1
Significant reductions in body weight have been observed in multiple clinical studies, with some participants losing a substantial percentage of total body weight.
2
Improvements in blood sugar regulation have been reported across study populations.
3
Research suggests broader metabolic effects than earlier single- or dual-pathway compounds in the same class.
4
Large Phase 3 clinical studies are currently ongoing.
5
Long-term safety and durability of effects continue to be evaluated in active research programs.

Want to understand why these findings occur? Continue to the scientific overview below.

The Science Behind It

Retatrutide is a synthetic peptide agonist that simultaneously targets three incretin receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG). This triple-receptor activity profile distinguishes it from dual agonists and has made it a subject of significant interest in metabolic research. The compound is classified as a long-acting acylated peptide designed for subcutaneous administration in preclinical and clinical research settings.

Mechanism of Action

Retatrutide engages GLP-1 receptors to potentiate glucose-dependent insulin secretion and suppress glucagon release. Concurrent GIP receptor activation augments the insulinotropic response and may contribute to adipose tissue remodeling. The glucagon receptor component is hypothesized to increase hepatic glucose output regulation and energy expenditure. The integrated signaling across all three axes is studied for its potential to produce additive or synergistic effects on metabolic homeostasis beyond what single or dual agonism achieves.

Key Research Characteristics
Triple incretin receptor agonist targeting GLP-1R, GIPR, and GCGR simultaneously
Long-acting acylated peptide with extended plasma half-life suitable for in vivo research protocols
Studied for synergistic metabolic effects exceeding those of single or dual receptor agonism
Glucagon receptor component investigated for hepatic energy expenditure and lipolysis modulation
Subject of Phase 3 clinical investigation; robust published pharmacology literature available
Useful tool compound for comparative incretin receptor pharmacology studies

Research Applications

Metabolic syndrome and obesity research models
Glucose homeostasis and insulin sensitivity studies
Adipose tissue biology and lipid metabolism research
Comparative incretin pharmacology studies
Energy expenditure and thermogenesis investigation

Compound Specifications

Available Strength
10 mg / vial
Appearance
White to off-white lyophilized powder
Purity
≥98% (HPLC)
Storage Conditions
−20 °C; protect from light and moisture
Storage After Reconstitution
4 °C up to 7 days; −80 °C for long-term storage
Molecular Formula
C₂₂₂H₃₆₆N₆₂O₆₅
Molecular Weight
4867.4 g/mol
CAS Number
2381089-83-2
Research Status
Research Use Only (RUO)

Scientific References

1.Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514–526.
2.Coskun T, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycemic control and weight loss. Mol Metab. 2022;66:101651.
3.Finan B, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151.
4.[Placeholder] Peer-reviewed publication on GCG receptor contribution to energy expenditure in triple agonist models.
5.[Placeholder] Technical reference: receptor binding affinity and selectivity profile for Retatrutide.

Placeholder entries are reserved for peer-reviewed publications. All references are provided for scientific context only.

Current State of Research

Research Use Only

All information presented on this Research Profile is intended exclusively for laboratory research purposes. This compound is designated Research Use Only (RUO) and is not intended for human consumption, veterinary use, or any clinical application. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition.

This material is sold solely for in vitro research and laboratory investigation by qualified scientific personnel. Kali Research LLC makes no representations regarding the safety or efficacy of this compound for any use outside of controlled laboratory research settings. Researchers are solely responsible for compliance with all applicable laws and institutional regulations governing the use of research compounds.

Not for human consumptionNot for veterinary useNot for clinical applicationQualified researchers onlyIn vitro / laboratory use
Research Inquiry

Request Information

Need additional technical documentation on Retatrutide? Submit an inquiry and a member of our team will respond.

Research Profile
Specifications
Available Strength10 mg / vial
AppearanceWhite to off-white lyophilized powder
Purity≥98% (HPLC)
Storage Conditions−20 °C; protect from light and moisture
Storage After Reconstitution4 °C up to 7 days; −80 °C for long-term storage
Molecular FormulaC₂₂₂H₃₆₆N₆₂O₆₅
Molecular Weight4867.4 g/mol
CAS Number2381089-83-2

Need additional technical documentation? Submit an inquiry and our team will respond.

Research Use Only (RUO). Not for human consumption, veterinary use, or clinical application.